Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases

Elizabeth C. Mormino, Tyler N. Toueg, Carmen Azevedo, Jessica B. Castillo, Wanjia Guo, Ayesha Nadiadwala, Nicole K. Corso, Jacob N. Hall, Audrey Fan, Alexandra N. Trelle, Marc B. Harrison, Madison P. Hunt, Sharon J. Sha, Gayle Deutsch, Michelle James, Carolyn A. Fredericks, Mary Ellen Koran, Michael Zeineh, Kathleen Poston, Michael D. GreiciusMehdi Khalighi, Guido A. Davidzon, Bin Shen, Greg Zaharchuk, Anthony D. Wagner, Frederick T. Chin

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Purpose: In vivo measurement of the spatial distribution of neurofibrillary tangle pathology is critical for early diagnosis and disease monitoring of Alzheimer’s disease (AD). Methods: Forty-nine participants were scanned with 18F-PI-2620 PET to examine the distribution of this novel PET ligand throughout the course of AD: 36 older healthy controls (HC) (age range 61 to 86), 11 beta-amyloid+ (Aβ+) participants with cognitive impairment (CI; clinical diagnosis of either mild cognitive impairment or AD dementia, age range 57 to 86), and 2 participants with semantic variant primary progressive aphasia (svPPA, age 66 and 78). Group differences in brain regions relevant in AD (medial temporal lobe, posterior cingulate cortex, and lateral parietal cortex) were examined using standardized uptake value ratios (SUVRs) normalized to the inferior gray matter of the cerebellum. Results: SUVRs in target regions were relatively stable 60 to 90 min post-injection, with the exception of very high binders who continued to show increases over time. Robust elevations in 18F-PI-2620 were observed between HC and Aβ+ CI across all AD regions. Within the HC group, older age was associated with subtle elevations in target regions. Mildly elevated focal uptake was observed in the anterior temporal pole in one svPPA patient. Conclusion: Preliminary results suggest strong differences in the medial temporal lobe and cortical regions known to be impacted in AD using 18F-PI-2620 in patients along the AD trajectory. This work confirms that 18F-PI-2620 holds promise as a tool to visualize tau aggregations in AD.

Original languageEnglish (US)
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
StateAccepted/In press - 2020
Externally publishedYes


  • Alzheimer’s disease
  • Human aging
  • Neurofibrillary tangles
  • Tau PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Tau PET imaging with <sup>18</sup>F-PI-2620 in aging and neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this